Oncolaxy is indicated for the follow-up of cancer patients, allowing the analysis of the global evolution of biomedical dynamics with the aim of detecting progression, recurrence or therapeutic toxicity.
Oncolaxy is a Class IIa Medical Device bearing the CE mark according to the regulations.
For support in using the service, contact us by e-mail: support@oncolaxy.care
Oncolaxy allows the follow-up and support of cancer patients - regardless of the type of cancer, stage or treatment. It offers a unique approach in Europe.
Oncolaxy is a software package indicated for remote monitoring of cancer patients.
Oncolaxy allows the automatic detection of recurrences or complications related to therapies. It results in an improvement in patients’ quality of life and an increase in overall survival.
It is a Class IIa Medical Device declared to the ANSM, designed according to ISO 13485 certified procedures.
Oncolaxy was created by Betterise, an independent French company that has supported more than 500,000 patients since 2013.
.png)
Oncolaxy provides reliable and secure assistance to caregivers in managing their patients remotely thanks to three main features:
Patients are sent a weekly questionnaire by SMS to report their symptoms in a few minutes.
The questionnaire can also be received by e-mail.
.png)
The data is analysed and if any anomalies are detected, an alert is sent by e-mail.
The care team can access a clear table at any time to understand the patient’s health status and how it changed over the last few weeks.
This allows the care to be adapted if necessary.
.png)
Patients have access to therapeutic education content adapted to their reported symptoms and pathology, to help them better understand what they should do and can do on a daily basis.
This reduces the burden on care teams and allows them to focus on patients who require more comprehensive support.
.png)
Basch E,Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017;318(2):197-198.
Laugsand EA, Sprangers MAG, Bjordal K, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes. 2010;8:104.
Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21:1159-1164.
Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014; 32:1480-1501.
Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26:1846-1858.
Denis F, Basch E, Septans AL, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA. 2019;321(3):306-307
Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016;34(6):557-565.
Oncolaxy meets the most stringent regulatory requirements in terms of quality and safety
Oncolaxy is a Class IIa Medical Device,
registered in EUDAMED,
bearing the CE mark.
We’re certified by GMED as meeting the requirements of the international standard ISO 13485.
We’re aligned with the requirements of PGSSI-S / ISO 27001: the safety of patients and the security of their data is ensured.
We comply with the GDPR requirements on data processing and the provision of good information to our users.
Simply send us an e-mail and our team will contact you as soon as possible:
contact@betterise-healthtech.com
Name: Oncolaxy
Indication: Oncolaxy is indicated for the follow-up of cancer patients, allowing the analysis of the global evolution of biomedical dynamics with the aim of detecting progression, recurrence or therapeutic toxicity.
Date of last modification: V2.0.0, 19.11.2020
Regulatory information
Oncolaxy is a clinical decision support software used to monitor cancers during their evolution (during treatment and surveillance phases), in addition to conventional monitoring.
Oncolaxy allows the analysis of the global evolution of the bio-medical dynamics in order to detect evolution, recurrence or toxicity of a therapy.
Oncolaxy is a Medical Device bearing the CE mark
In accordance with rule 10 of Annex IX of Directive 93/42/EEC, Oncolaxy is classified as a Class IIa device.
Oncolaxy is manufactured by Betterise Technologies, 24 Avenue Victor Hugo 64200 Biarritz FRANCE, under certified procedures that comply with the requirements of the international standard ISO 13485:2016.
This medical device is a regulated health product that bears, under this regulation, the CE marking
All users are advised to read the instructions for use provided before first use.
For any question or request for assistance, please contact the support by email : support@oncolaxy.care
